# A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

Study · id `cardio:ct-nct06458907` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06458907](<https://clinicaltrials.gov/study/NCT06458907>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06458907

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 780 participants.

## Technical summary

Registry record NCT06458907. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2028-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 780 participants (planned count; ClinicalTrials.gov record NCT06458907, source copy `cardio:ctgov-nct06458907-2026-11-17`, retrieved 2026-11-18)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT06458907, source copy `cardio:ctgov-nct06458907-2026-11-17`, retrieved 2026-11-18)
- Primary completion: 2028-11 (anticipated) (ClinicalTrials.gov record NCT06458907, source copy `cardio:ctgov-nct06458907-2026-11-17`, retrieved 2026-11-18)
- Completion: 2032-11 (anticipated) (ClinicalTrials.gov record NCT06458907, source copy `cardio:ctgov-nct06458907-2026-11-17`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT06458907, source copy `cardio:ctgov-nct06458907-2026-11-17`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06458907-2026-11-17`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.
- Acronym: TRICAV-II
- Condition: Tricuspid Valve Disease
- Condition: Heart Valve Diseases
- Condition: Cardiovascular Diseases
- Condition: Heart Failure
- Condition: Tricuspid Valve Regurgitation
- Condition: Tricuspid Valve Insufficiency
- Intervention (Device): TricValve System
- Intervention (Drug): Optimal medical therapy
- Lead sponsor: P+F Products + Features USA Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Meditrial USA Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)

## Provenance

Content hash: 63f0e332ff130330fab97be837344bb7558e4170851573e8822cda25af044a9b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
